Eduardo A. Veliz , Athina Yoham , Anastasiya Drandarov , Esther L. Abadi , Emanuella M. Brito , Maria Moreno Hollweg , Venkatesh Shanbhag , Roger M. Leblanc , Steven Vanni , Regina M. Graham
{"title":"Cytotoxic effects of Methoxy-substituted Chalcones on glioblastoma stem cells: Computational target prediction and therapeutic insights","authors":"Eduardo A. Veliz , Athina Yoham , Anastasiya Drandarov , Esther L. Abadi , Emanuella M. Brito , Maria Moreno Hollweg , Venkatesh Shanbhag , Roger M. Leblanc , Steven Vanni , Regina M. Graham","doi":"10.1016/j.rechem.2025.102122","DOIUrl":null,"url":null,"abstract":"<div><div>The prognosis for patients diagnosed with glioblastoma remains dismal with an average survival of about 15 months. Recently, it has been shown that glioblastoma stem-like cells (GSCs) drive tumor progression and are responsible for tumor regrowth following treatment; therefore, successful elimination of this cell population is necessary for disease eradication. Methoxy substituted chalcones have demonstrated anti-cancer effects with diverse molecular mechanisms. In this study, we synthesized 24 methoxy containing compounds, including 5 novel compounds, and tested their cytotoxicity toward 3 GSC lines and 2 non-tumor cell lines. We identified 13 compounds demonstrating an average GSC IC<sub>50</sub> value below 10 μM, many of which were less toxic to the non-cancer cell lines. <em>In silico</em> reverse screening identified probable targets for 7 out of the 13 active compounds. Some targets have been well-investigated such as the epidermal growth factor receptor; however, others such as 17-beta hydroxysteroid dehydrogenase type 3 warrant further study.</div></div>","PeriodicalId":420,"journal":{"name":"Results in Chemistry","volume":"14 ","pages":"Article 102122"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Results in Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211715625001055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
The prognosis for patients diagnosed with glioblastoma remains dismal with an average survival of about 15 months. Recently, it has been shown that glioblastoma stem-like cells (GSCs) drive tumor progression and are responsible for tumor regrowth following treatment; therefore, successful elimination of this cell population is necessary for disease eradication. Methoxy substituted chalcones have demonstrated anti-cancer effects with diverse molecular mechanisms. In this study, we synthesized 24 methoxy containing compounds, including 5 novel compounds, and tested their cytotoxicity toward 3 GSC lines and 2 non-tumor cell lines. We identified 13 compounds demonstrating an average GSC IC50 value below 10 μM, many of which were less toxic to the non-cancer cell lines. In silico reverse screening identified probable targets for 7 out of the 13 active compounds. Some targets have been well-investigated such as the epidermal growth factor receptor; however, others such as 17-beta hydroxysteroid dehydrogenase type 3 warrant further study.